The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Anand is committed to leading the company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, AI and LLM
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Subscribe To Our Newsletter & Stay Updated
